Dyadic to Present at BIO CEO and Investor Conference
February 13 2006 - 8:01AM
Business Wire
Dyadic International, Inc. (AMEX:DIL), a biotechnology company
engaged in the development, manufacture and sale of biological
products, announced today that its President and CEO, Mark
Emalfarb, will present at the BIO CEO and Investor Conference, to
be held on February 13-15, 2006 at The Waldorf Astoria Hotel in New
York City. The presentation will take place in the Empire Room at
11:30 AM EST on Tuesday, February 14, 2006. Presentation slides
will be available on the Dyadic website at
http://www.dyadic-group.com. The 2006 Biotechnology Industry
Organization CEO & Investor Conference will highlight
commercial advances in bioethanol. Dyadic has devoted significant
R&D resources over the last decade towards developing its C1
Host Technology and other proprietary technologies to produce
cellulases and other important enzymes that convert cellulosic
substrates such as corn stover and sugar cane bagasse into glucose
from which bioethanol can be produced, and which are therefore
expected by Dyadic to have direct applicability to the bioethanol
segment of the industry. For additional information, please also
see the Biotechnology Industry Organization press release entitled
"BIO CEO and Investor Conference to Highlight Commercial Advances
in Bioethanol," available at
http://www.bio.org/news/newsitem.asp?id=2006_0201_02. Neither BIO's
press release nor any information on its website is incorporated by
reference in this press release. The conference, now in its 8th
year, is designed to educate new investors and media on the value,
risks and rewards offered by the industry and to fuel continued
industry growth and investments in 2006. Complimentary registration
is open to qualified investors and members of the media at
http://www.ceo.bio.org. About Dyadic Dyadic International, Inc., is
engaged in the development, manufacture and sale of proteins,
enzymes and other bio-molecules, as well as the licensing of its
enabling proprietary technology to collaborators for the discovery,
development and manufacture of biological products from genes.
Dyadic markets its products and services for applications in the
textile, chemical, agricultural, pulp & paper, pharmaceutical,
biotechnology and other industries, using its proprietary C1 Host
Technology and C1 Expression and Screening Systems for the
discovery, development and production of biological products.
Cautionary Statement for Forward-Looking Statements Certain
statements contained in this press release are "forward-looking
statements." These forward-looking statements involve risks and
uncertainties that could cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by such
forward-looking statements. For a discussion of these risks and
uncertainties, please see our filings from time to time with the
Securities and Exchange Commission, which are available free of
charge on the SEC's web site at http://www.sec.gov, including our
Annual Report on Form 10-KSB for the year ended December 31, 2004,
and our Quarterly Report on Form 10-QSB for the quarter ended
September 30, 2005. Except as required by law, we expressly
disclaim any intent or obligation to update any forward-looking
statements.
Dyadic (AMEX:DIL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Dyadic (AMEX:DIL)
Historical Stock Chart
From Jul 2023 to Jul 2024